Tizard
Joseph Henry Tizard, Skokie, IL US
Patent application number | Description | Published |
---|---|---|
20150111266 | CARBON CAPTURE IN FERMENTATION - The invention provides processes and methods for utilization of carbon dioxide (CO | 04-23-2015 |
Mark Leslie Tizard, Highton AU
Patent application number | Description | Published |
---|---|---|
20150024488 | NUCLEIC ACID COMPLEX - The present invention relates to a complex comprising a cationic block copolymer and a nucleic acid, the cationic block copolymer having at least a tri-block structure comprising a cationic block and two hydrophilic blocks, or a hydrophilic block and two cationic blocks. | 01-22-2015 |
20150056158 | BRANCHED POLYMERS - The present invention relates to branched polymer comprising a support moiety and at least three block co-polymer chains covalently coupled to and extending from the moiety, wherein: (i) each of the at least three block co-polymer chains comprise (a) a cationic polymer block that is covalently coupled to a hydrophilic polymer block, or (b) a cationic polymer block that is covalently coupled to a hydrophobic polymer block, said hydrophobic polymer block being covalently coupled to a hydrophilic polymer block; and (ii) at least one of said covalent couplings associated with each of said block co-polymer chains is biodegradable. | 02-26-2015 |
Richard Tizard, Framingham, MA US
Patent application number | Description | Published |
---|---|---|
20100041032 | COMPOSITION AND METHODS FOR THE DETECTION OF CRIPTO-3 - The present invention is based, at least in part, on the discovery that the pseudogene TDGF3 (Cripto-3) is expressed in cells and, in particular, that TDGF3 overexpression is associated with transformation of a cell, e.g., TDGF3 is overexpressed in cancer cell lines and cells from tumor tissue. Accordingly, the invention provides compositions, kits, and methods for detecting the presence of a TDGF3 polynucleotide or polypeptide in a sample. The invention further provides compositions, kits and methods for assessing whether a cell is transformed as well as for assessing whether a patient is a suitable candidate for an anti-Cripto antibody therapy. | 02-18-2010 |